Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Director | June 05, 2026 | June 15, 2026 |
| Krystal Biotech, Inc.KRYS · Entity 3500 | Chief Business Officer | January 31, 2022 | January 31, 2022 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | CHIEF MEDICAL OFFICER | February 17, 2026 | February 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcturus Therapeutics Holdings Inc.
Report date June 05, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2036-06-05 | Direct | 15,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 15,000 · Balance 15,000 F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
Krystal Biotech, Inc.
Report date January 31, 2022 · Filed January 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.00 · Expires 2032-01-31 | Direct | 205,000 |
Reported balance
After 2022-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-31 · Grant · Acquired 205,000 · Balance 205,000 F1: The options were awarded on January 31, 2022 and vest in four equal annual installments beginning on January 31, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were awarded on January 31, 2022 and vest in four equal annual installments beginning on January 31, 2023.
Scholar Rock Holding Corp
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,012 |
Reported balance
After 2026-02-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-17 · Sale · Disposed 4,157 · Balance 126,012 F1: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSU") on February 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. The shares vested pursuant to awards that were granted on February 13, 2023 and March 10, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date. F2: Consists of 29,388 shares of common stock and 96,624 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSU") on February 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. The shares vested pursuant to awards that were granted on February 13, 2023 and March 10, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date.
F2: Consists of 29,388 shares of common stock and 96,624 RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 15, 2026 21:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001193805-26-000823 · e665578_4-jing.xml · derivative · entry 1 Marantz Jing L. · CIK 0001834528 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-06-05 F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 4,157 | $46.53 | $193,417.73 |
DisclosureSEC source: 0001834528-26-000005 · form4-02192026_040209.xml · nonDerivative · entry 1 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,012 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSU") on February 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. The shares vested pursuant to awards that were granted on February 13, 2023 and March 10, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date. F2 · balance_after: Consists of 29,388 shares of common stock and 96,624 RSUs. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 23:09 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 34,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-013582 · tm266077-4_4seq1.xml · nonDerivative · entry 1 Marantz Jing L. · CIK 0001834528 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,169 F1 · shares: Represents restricted stock units ("RSUs") subject to time-based vesting conditions. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on January 15, 2027 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. F2 · balance_after: Consists of 24,974 shares of common stock and 105,195 RSUs. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 00:50 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 5,798 | $44.48 | $257,881.70 |
DisclosureSEC source: 0001834528-26-000003 · form4-01222026_120152.xml · nonDerivative · entry 1 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,687 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSU") on January 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. The shares vested pursuant to awards that were granted on February 12, 2024. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards are fully vested. F2 · balance_after: Consists of 24,974 shares of common stock and 70,713 RSUs. Read SEC document |
| June 09, 2025 Filed Jun 12, 2025 00:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $12.54 | $0.00 |
DisclosureSEC source: 0001193805-25-000874 · e664620_4-jing.xml · derivative · entry 1 Marantz Jing L. · CIK 0001834528 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-09 F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:00 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 45,715 | $0.00 Strike: $35.15 | $0.00 |
DisclosureSEC source: 0001415889-25-007840 · form4-03122025_050314.xml · derivative · entry 2 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,715 Underlying: Common Stock · 45,715 shares Expires 2035-03-10 F3 · derivative.exercise_date: Options to vest in sixteen quarterly installments over four years, with the first quarterly installment to vest on April 1, 2025 and each additional installment to vest quarterly thereafter; provided the individual continues to have a service relationship with the Issuer on such vesting date. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:00 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 34,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007840 · form4-03122025_050314.xml · nonDerivative · entry 1 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,485 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on February 15, 2026 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on such vesting date. F2 · balance_after: Consists of 12,558 shares of common stock and 88,927 RSUs Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 21:35 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 5,655 | $44.20 | $249,935.17 |
DisclosureSEC source: 0001415889-25-001794 · form4-01212025_040113.xml · nonDerivative · entry 1 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,200 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSU") on January 15, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on February 12, 2024. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date. F2 · balance_after: Consists of 12,558 shares of common stock and 54,642 RSUs. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 22:00 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,375 | $0.00 Strike: $8.59 | $0.00 |
DisclosureSEC source: 0001104659-24-123157 · tm2429564-1_4seq1.xml · derivative · entry 9 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 6,375 shares Expires 2032-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. F7 · derivative.exercise_date: The shares underlying this option vest over four years with the first installment vested on November 9, 2023 and the remainder vesting in twelve quarterly installments thereafter, provided the reporting person continues to have a service relationship with the Issuer as of the applicable vesting date. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 22:00 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 200 | $40.72 | $8,144.00 |
DisclosureSEC source: 0001104659-24-123157 · tm2429564-1_4seq1.xml · nonDerivative · entry 7 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,855 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.65 to $40.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 22:00 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 3,075 | $39.93 | $122,780.14 |
DisclosureSEC source: 0001104659-24-123157 · tm2429564-1_4seq1.xml · nonDerivative · entry 6 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,055 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 22:00 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 2,100 | $39.25 | $82,434.03 |
DisclosureSEC source: 0001104659-24-123157 · tm2429564-1_4seq1.xml · nonDerivative · entry 5 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,130 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.64 to $39.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 22:00 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 1,000 | $38.04 | $38,041.00 |
DisclosureSEC source: 0001104659-24-123157 · tm2429564-1_4seq1.xml · nonDerivative · entry 4 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,230 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.63 to $38.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 22:00 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | Exercise / conversionCommon Stock | 6,375 | $8.59 | $54,761.25 |
DisclosureSEC source: 0001104659-24-123157 · tm2429564-1_4seq1.xml · nonDerivative · entry 3 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 22:00 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,145 | $0.00 Strike: $8.59 | $0.00 |
DisclosureSEC source: 0001104659-24-123157 · tm2429564-1_4seq1.xml · derivative · entry 8 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,375 Underlying: Common Stock · 2,145 shares Expires 2032-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. F7 · derivative.exercise_date: The shares underlying this option vest over four years with the first installment vested on November 9, 2023 and the remainder vesting in twelve quarterly installments thereafter, provided the reporting person continues to have a service relationship with the Issuer as of the applicable vesting date. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 22:00 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 2,145 | $30.01 | $64,371.88 |
DisclosureSEC source: 0001104659-24-123157 · tm2429564-1_4seq1.xml · nonDerivative · entry 2 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,855 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 22:00 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | Exercise / conversionCommon Stock | 2,145 | $8.59 | $18,425.55 |
DisclosureSEC source: 0001104659-24-123157 · tm2429564-1_4seq1.xml · nonDerivative · entry 1 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:40 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,105 | $0.00 Strike: $8.59 | $0.00 |
DisclosureSEC source: 0001415889-24-026708 · form4-11132024_041101.xml · derivative · entry 3 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,520 Underlying: Common Stock · 2,105 shares Expires 2032-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. F3 · derivative.exercise_date: The shares underlying this option vest over four years with the first installment vested on November 9, 2023 and the remainder vesting in twelve quarterly installments thereafter, provided the reporting person continues to have a service relationship with the Issuer as of the applicable vesting date. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:40 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 2,105 | $30.00 | $63,158.42 |
DisclosureSEC source: 0001415889-24-026708 · form4-11132024_041101.xml · nonDerivative · entry 2 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,855 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:40 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | Exercise / conversionCommon Stock | 2,105 | $8.59 | $18,081.95 |
DisclosureSEC source: 0001415889-24-026708 · form4-11132024_041101.xml · nonDerivative · entry 1 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 00:51 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | Exercise / conversionStock Option (Right to Buy) · Derivative | 109,375 | $0.00 Strike: $8.59 | $0.00 |
DisclosureSEC source: 0001104659-24-106797 · tm2425784-2_4seq1.xml · derivative · entry 5 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,625 Underlying: Common Stock · 109,375 shares Expires 2032-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Options vest over four years with 25% vesting on November 9, 2023 and the remainder vesting in 12 quarterly installments thereafter, provided the reporting person continues to have a service relationship with the Issuer as of the applicable vesting date. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 00:51 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 39,375 | $30.06 | $1,183,651.88 |
DisclosureSEC source: 0001104659-24-106797 · tm2425784-2_4seq1.xml · nonDerivative · entry 4 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,855 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 00:51 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 2,552 | $26.22 | $66,922.63 |
DisclosureSEC source: 0001104659-24-106797 · tm2425784-2_4seq1.xml · nonDerivative · entry 3 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,230 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.20 to $26.335, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 00:51 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 67,448 | $25.59 | $1,725,893.15 |
DisclosureSEC source: 0001104659-24-106797 · tm2425784-2_4seq1.xml · nonDerivative · entry 2 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,782 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.15 to $26.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 00:51 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | Exercise / conversionCommon Stock | 109,375 | $8.59 | $939,531.25 |
DisclosureSEC source: 0001104659-24-106797 · tm2425784-2_4seq1.xml · nonDerivative · entry 1 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $31.00 | $0.00 |
DisclosureSEC source: 0001193805-24-000829 · e663730_4-jing.xml · derivative · entry 3 Marantz Jing L. · CIK 0001834528 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-06-14 F3 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F3 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | Exercise / conversionDeferred Stock Units · Derivative | 3,131 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193805-24-000829 · e663730_4-jing.xml · derivative · entry 2 Marantz Jing L. · CIK 0001834528 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,131 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. F1 · derivative.exercise_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. F1 · derivative.expiration_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | Exercise / conversionCommon Stock | 3,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-24-000829 · e663730_4-jing.xml · nonDerivative · entry 1 Marantz Jing L. · CIK 0001834528 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. F1 · price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 00:16 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 97,145 | $0.00 Strike: $15.75 | $0.00 |
DisclosureSEC source: 0001415889-24-003629 · form4-02142024_120206.xml · derivative · entry 2 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,145 Underlying: Common Stock · 97,145 shares Expires 2034-02-12 F3 · derivative.exercise_date: Options to vest in sixteen quarterly installments over four years, with the first quarterly installment to vest on April 1, 2024 and each additional installment to vest quarterly thereafter; provided the individual continues to have a service relationship with the Issuer on such vesting date. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 00:16 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 72,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-003629 · form4-02142024_120206.xml · nonDerivative · entry 1 Marantz Jing L. · CIK 0001834528 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,855 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on January 15, 2025 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on such vesting date. F2 · balance_after: Consists solely of RSUs. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:12 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantDeferred Stock Units · Derivative | 3,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-23-001072 · e618810_4-jing.xml · derivative · entry 2 Marantz Jing L. · CIK 0001834528 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,131 Underlying: Common Stock · 3,131 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock. F3 · derivative.exercise_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F3 · derivative.expiration_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:12 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 11,869 | $0.00 Strike: $34.92 | $0.00 |
DisclosureSEC source: 0001193805-23-001072 · e618810_4-jing.xml · derivative · entry 1 Marantz Jing L. · CIK 0001834528 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,869 Underlying: Common Stock · 11,869 shares Expires 2033-08-01 F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant; provided however, that the remaining unvested balance will vest and become fully exercisable at the Issuer's 2024 annual meeting of stockholders. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 22:35 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $8.59 | $0.00 |
DisclosureSEC source: 0001104659-22-119209 · tm2230637-2_4seq1.xml · derivative · entry 1 Marantz Jing L. · CIK 0001834528 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-11-14 F1 · derivative.exercise_date: Options vest over four years with 25% vesting on November 9, 2023 and the remainder vesting in 12 quarterly installments thereafter, provided the reporting person continues to have a service relationship with the Issuer as of the applicable vesting date. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 23:16 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $16.02 | $0.00 |
DisclosureSEC source: 0001193805-22-001022 · e621783_4-jing.xml · derivative · entry 1 Marantz Jing L. · CIK 0001834528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors. Read SEC document |
| January 31, 2022 Filed Jan 31, 2022 22:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 205,000 | $0.00 Strike: $59.00 | $0.00 |
DisclosureSEC source: 0001834528-22-000003 · wf-form4_164366801686527.xml · derivative · entry 1 Marantz Jing L. · CIK 0001834528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 205,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: The options were awarded on January 31, 2022 and vest in four equal annual installments beginning on January 31, 2023. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 01:13 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 6,699 | $0.00 Strike: $38.54 | $0.00 |
DisclosureSEC source: 0001193805-21-001718 · e621146_4-jing.xml · derivative · entry 2 Marantz Jing L. · CIK 0001834528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,699 Underlying: Common Stock · 6,699 shares Expires 2031-12-06 F2 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the annual grant to the Reporting Person as a member of the Board, prorated based on the date the Reporting Person was appointed to the Board, representing an estimated six months of service. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 01:13 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $38.54 | $0.00 |
DisclosureSEC source: 0001193805-21-001718 · e621146_4-jing.xml · derivative · entry 1 Marantz Jing L. · CIK 0001834528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-12-06 F1 · derivative.exercise_date: Shares underlying the option vest monthly over a two year period from the date of grant. This represents the initial grant to the Reporting Person as a member of the Board of Directors (the "Board"). Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 15:26 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 6,800 | $0.00 Strike: $68.00 | $0.00 |
DisclosureSEC source: 0001711279-21-000014 · wf-form4_162523956297359.xml · derivative · entry 1 Marantz Jing L. · CIK 0001834528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2031-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2021 and vest in equal monthly tranches over a one-year period. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 13,600 | $0.00 Strike: $59.42 | $0.00 |
DisclosureSEC source: 0000899243-21-000413 · doc4.xml · derivative · entry 1 Marantz Jing L. · CIK 0001834528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,600 Underlying: Common Stock · 13,600 shares Expires 2031-01-04 F1 · derivative.exercise_date: The options were awarded on January 4, 2021 and vest in equal amounts over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.